Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

T Cell- and Monocyte-Specific RNA-Sequencing Analysis in Septic and Nonseptic Critically Ill Patients and in Patients with Cancer.

Washburn ML, Wang Z, Walton AH, Goedegebuure SP, Figueroa DJ, Van Horn S, Grossman J, Remlinger K, Madsen H, Brown J, Srinivasan R, Wolf AI, Berger SB, Yi VN, Hawkins WG, Fields RC, Hotchkiss RS.

J Immunol. 2019 Oct 1;203(7):1897-1908. doi: 10.4049/jimmunol.1900560. Epub 2019 Sep 4.

PMID:
31484735
2.

Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles.

Strand MS, Krasnick BA, Pan H, Zhang X, Bi Y, Brooks C, Wetzel C, Sankpal N, Fleming T, Goedegebuure SP, DeNardo DG, Gillanders WE, Hawkins WG, Wickline SA, Fields RC.

Oncotarget. 2019 Jul 30;10(46):4761-4775. doi: 10.18632/oncotarget.27109. eCollection 2019 Jul 30.

3.

A 22-year experience with pancreatic resection for metastatic renal cell carcinoma.

Anderson B, Williams GA, Sanford DE, Lu J, Dageforde LA, Hammill CW, Fields RC, Hawkins WG, Strasberg SM, Doyle MB, Chapman WC, Khan AS.

HPB (Oxford). 2019 Jul 23. pii: S1365-182X(19)30569-6. doi: 10.1016/j.hpb.2019.05.019. [Epub ahead of print]

PMID:
31345661
4.

Association of preoperative monocyte-to-lymphocyte and neutrophil-to-lymphocyte ratio with recurrence-free and overall survival after resection of pancreatic neuroendocrine tumors (US-NETSG).

Panni RZ, Lopez-Aguiar AG, Liu J, Poultsides GA, Rocha FG, Hawkins WG, Strasberg SM, Trikalinos NA, Maithel S, Fields RC; and other members of US-NETSG.

J Surg Oncol. 2019 Sep;120(4):632-638. doi: 10.1002/jso.25629. Epub 2019 Jul 24.

PMID:
31339198
5.

Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.

Macedo FI, Ryon E, Maithel SK, Lee RM, Kooby DA, Fields RC, Hawkins WG, Williams G, Maduekwe U, Kim HJ, Ahmad SA, Patel SH, Abbott DE, Schwartz P, Weber SM, Scoggins CR, Martin RCG, Dudeja V, Franceschi D, Livingstone AS, Merchant NB.

Ann Surg. 2019 Sep;270(3):400-413. doi: 10.1097/SLA.0000000000003468.

PMID:
31283563
6.

Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies.

Panni RZ, Herndon JM, Zuo C, Hegde S, Hogg GD, Knolhoff BL, Breden MA, Li X, Krisnawan VE, Khan SQ, Schwarz JK, Rogers BE, Fields RC, Hawkins WG, Gupta V, DeNardo DG.

Sci Transl Med. 2019 Jul 3;11(499). pii: eaau9240. doi: 10.1126/scitranslmed.aau9240.

PMID:
31270275
7.

Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions.

Das KK, Geng X, Brown JW, Morales-Oyarvide V, Huynh T, Pergolini I, Pitman MB, Ferrone C, Al Efishat M, Haviland D, Thompson E, Wolfgang C, Lennon AM, Allen P, Lillemoe KD, Fields RC, Hawkins WG, Liu J, Castillo CF, Das KM, Mino-Kenudson M.

Gastroenterology. 2019 Sep;157(3):720-730.e2. doi: 10.1053/j.gastro.2019.05.014. Epub 2019 Jun 5.

PMID:
31175863
8.

Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.

Prudner BC, Rathore R, Robinson AM, Godec A, Chang SF, Hawkins WG, Hirbe AC, Van Tine BA.

Clin Cancer Res. 2019 Aug 15;25(16):5122-5134. doi: 10.1158/1078-0432.CCR-19-0206. Epub 2019 May 21.

PMID:
31113844
9.

Pancreatic Adenocarcinoma, Version 1.2019.

Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210. doi: 10.6004/jnccn.2019.0014.

PMID:
30865919
10.

A diagnosis reconsidered: the symptomatic gallbladder remnant.

Grossman JG, Johnston WR, Fowler KJ, Williams GA, Hammill CW, Hawkins WG.

J Hepatobiliary Pancreat Sci. 2019 Apr;26(4):137-143. doi: 10.1002/jhbp.613. Epub 2019 Apr 3.

PMID:
30821072
11.

National Pancreatic Fistula Rates after Minimally Invasive Pancreaticoduodenectomy: A NSQIP Analysis.

Panni RZ, Guerra J, Hawkins WG, Hall BL, Asbun HJ, Sanford DE.

J Am Coll Surg. 2019 Aug;229(2):192-199.e1. doi: 10.1016/j.jamcollsurg.2019.02.042. Epub 2019 Feb 21.

PMID:
30797082
12.

TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death.

Zeng C, Weng CC, Schneider ME Jr, Puentes L, Riad A, Xu K, Makvandi M, Jin L, Hawkins WG, Mach RH.

Cell Death Discov. 2019 Jan 28;5:58. doi: 10.1038/s41420-019-0141-2. eCollection 2019.

13.

Long-Term Endocrine and Exocrine Insufficiency After Pancreatectomy.

Kusakabe J, Anderson B, Liu J, Williams GA, Chapman WC, Doyle MMB, Khan AS, Sanford DE, Hammill CW, Strasberg SM, Hawkins WG, Fields RC.

J Gastrointest Surg. 2019 Aug;23(8):1604-1613. doi: 10.1007/s11605-018-04084-x. Epub 2019 Jan 22.

14.

Recruitment of CCR2+ tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer.

Grossman JG, Nywening TM, Belt BA, Panni RZ, Krasnick BA, DeNardo DG, Hawkins WG, Goedegebuure SP, Linehan DC, Fields RC.

Oncoimmunology. 2018 Aug 1;7(9):e1470729. doi: 10.1080/2162402X.2018.1470729. eCollection 2018.

15.

Residual Tumor Index: A Prognostically Significant Pathologic Parameter in Neoadjuvant-treated Pancreatic Ductal Adenocarcinoma.

Panni RZ, Gonzalez I, Hartley CP, Williams GA, Liu J, Hawkins WG, Chatterjee D.

Am J Surg Pathol. 2018 Nov;42(11):1480-1487. doi: 10.1097/PAS.0000000000001144.

PMID:
30179901
16.

Synoptic operative reporting for laparoscopic cholecystectomy and pancreaticoduodenectomy: A multi institutional pilot study evaluating completeness and surgeon perceptions.

Deal SB, D'Angelica MI, Hawkins WG, Pucci M, Ujiki M, Brunt LM, Wexner S, Alseidi AA.

Am J Surg. 2018 Nov;216(5):935-940. doi: 10.1016/j.amjsurg.2018.06.008. Epub 2018 Jun 19.

PMID:
29937324
17.

The importance of early recognition in management of ERCP-related perforations.

Bill JG, Smith Z, Brancheck J, Elsner J, Hobbs P, Lang GD, Early DS, Das K, Hollander T, Doyle MBM, Fields RC, Hawkins WG, Strasberg SM, Hammill C, Chapman WC, Edmundowicz S, Mullady DK, Kushnir VM.

Surg Endosc. 2018 Dec;32(12):4841-4849. doi: 10.1007/s00464-018-6235-8. Epub 2018 May 16.

PMID:
29770887
18.

IL23 and TGF-ß diminish macrophage associated metastasis in pancreatic carcinoma.

Hussain SM, Reed LF, Krasnick BA, Miranda-Carboni G, Fields RC, Bi Y, Elahi A, Ajidahun A, Dickson PV, Deneve JL, Hawkins WG, Shibata D, Glazer ES.

Sci Rep. 2018 Apr 11;8(1):5808. doi: 10.1038/s41598-018-24194-5.

19.

Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.

Meyer MA, Baer JM, Knolhoff BL, Nywening TM, Panni RZ, Su X, Weilbaecher KN, Hawkins WG, Ma C, Fields RC, Linehan DC, Challen GA, Faccio R, Aft RL, DeNardo DG.

Nat Commun. 2018 Mar 28;9(1):1250. doi: 10.1038/s41467-018-03600-6.

20.

Utility of Endoscopic Ultrasound in Evaluating Local Recurrence After Surgery for Pancreatic Cancer.

Lang GD, Mullady DK, Early DS, Hollander T, Edmundowicz SA, Murad FM, Strasberg SM, Fields RC, Hawkins WG, Doyle MB, Chapman WC, Wang-Gillam A, Kushnir VM.

Clin Gastroenterol Hepatol. 2018 Nov;16(11):1834-1835. doi: 10.1016/j.cgh.2018.02.031. Epub 2018 Mar 2.

PMID:
29505906
21.

Epidurals in Pancreatic Resection Outcomes (E-PRO) study: protocol for a randomised controlled trial.

Pak LM, Haroutounian S, Hawkins WG, Worley L, Kurtz M, Frey K, Karanikolas M, Swarm RA, Bottros MM.

BMJ Open. 2018 Jan 26;8(1):e018787. doi: 10.1136/bmjopen-2017-018787.

22.

Optimal extent of surgical and pathologic lymph node evaluation for resected intrahepatic cholangiocarcinoma.

Brauer DG, Fields RC, Tan BR Jr, Doyle MBM, Hammill CW, Hawkins WG, Colditz GA, Chapman WC.

HPB (Oxford). 2018 May;20(5):470-476. doi: 10.1016/j.hpb.2017.11.010. Epub 2018 Jan 20.

23.

Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (σ2) receptor and P-gp protein in the cytotoxic action: In vitro and in vivo activity in pancreatic tumors.

Pati ML, Niso M, Spitzer D, Berardi F, Contino M, Riganti C, Hawkins WG, Abate C.

Eur J Med Chem. 2018 Jan 20;144:359-371. doi: 10.1016/j.ejmech.2017.12.024. Epub 2017 Dec 8.

24.

Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium.

Krasnick BA, Jin LX, Davidson JT 4th, Sanford DE, Ethun CG, Pawlik TM, Poultsides GA, Tran T, Idrees K, Hawkins WG, Chapman WC, Doyle MBM, Weber SM, Strasberg SM, Salem A, Martin RCG, Isom CA, Scoggins C, Schmidt CR, Shen P, Beal E, Hatzaras I, Shenoy R, Maithel SK, Fields RC.

J Surg Oncol. 2018 Mar;117(3):363-371. doi: 10.1002/jso.24836. Epub 2017 Dec 28.

25.

Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer.

Kuroki LM, Jin X, Dmitriev IP, Kashentseva EA, Powell MA, Mutch DG, Dietz AB, Curiel DT, Hawkins WG, Spitzer D.

PLoS One. 2017 Dec 21;12(12):e0190125. doi: 10.1371/journal.pone.0190125. eCollection 2017.

26.

Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma.

Nywening TM, Belt BA, Cullinan DR, Panni RZ, Han BJ, Sanford DE, Jacobs RC, Ye J, Patel AA, Gillanders WE, Fields RC, DeNardo DG, Hawkins WG, Goedegebuure P, Linehan DC.

Gut. 2018 Jun;67(6):1112-1123. doi: 10.1136/gutjnl-2017-313738. Epub 2017 Dec 1.

27.

Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium.

Schimizzi GV, Jin LX, Davidson JT 4th, Krasnick BA, Ethun CG, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Weber SM, Salem A, Hawkins WG, Strasberg SM, Doyle MB, Chapman WC, Martin RCG, Scoggins C, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Maithel SK, Fields RC.

HPB (Oxford). 2018 Apr;20(4):332-339. doi: 10.1016/j.hpb.2017.10.003. Epub 2017 Nov 21.

28.

Prospective Evaluation of Pasireotide in Patients Undergoing Pancreaticoduodenectomy: The Washington University Experience.

Dominguez-Rosado I, Fields RC, Woolsey CA, Williams G, Horwedel TA, Rose JB, Hammill CW, Doyle MB, Chapman WC, Strasberg SM, Hawkins WG, Sanford DE.

J Am Coll Surg. 2018 Feb;226(2):147-154.e1. doi: 10.1016/j.jamcollsurg.2017.10.021. Epub 2017 Nov 11.

PMID:
29133263
29.

Surgeon Variation in Intraoperative Supply Cost for Pancreaticoduodenectomy: Is Intraoperative Supply Cost Associated with Outcomes?

Brauer DG, Ohman KA, Jaques DP, Woolsey CA, Wu N, Liu J, Doyle MBM, Fields RC, Chapman WC, Strasberg SM, Hawkins WG.

J Am Coll Surg. 2018 Jan;226(1):37-45.e1. doi: 10.1016/j.jamcollsurg.2017.10.007. Epub 2017 Oct 19.

30.

Diagnosis and management of biliary injuries.

Rose JB, Hawkins WG.

Curr Probl Surg. 2017 Aug;54(8):406-435. doi: 10.1067/j.cpsurg.2017.06.001. Epub 2017 Jul 24. Review. No abstract available.

PMID:
28987473
31.

Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression.

Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, Cullinan DR, Luo J, Bearden AR, Lavine KJ, Yokoyama WM, Hawkins WG, Fields RC, Randolph GJ, DeNardo DG.

Immunity. 2017 Sep 19;47(3):597. doi: 10.1016/j.immuni.2017.08.018. No abstract available.

32.

Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression.

Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, Cullinan DR, Luo J, Bearden AR, Lavine KJ, Yokoyama WM, Hawkins WG, Fields RC, Randolph GJ, DeNardo DG.

Immunity. 2017 Aug 15;47(2):323-338.e6. doi: 10.1016/j.immuni.2017.07.014. Erratum in: Immunity. 2017 Sep 19;47(3):597.

33.

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S.

J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.

PMID:
28784865
34.

Flange Gastroenterostomy Results in Reduction in Delayed Gastric Emptying after Standard Pancreaticoduodenectomy: A Prospective Cohort Study.

Khan AS, Williams G, Woolsey C, Liu J, Fields RC, Doyle MMB, Hawkins WG, Strasberg SM.

J Am Coll Surg. 2017 Oct;225(4):498-507. doi: 10.1016/j.jamcollsurg.2017.06.006. Epub 2017 Jul 4.

35.

Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy.

Kim Y, Squires MH, Poultsides GA, Fields RC, Weber SM, Votanopoulos KI, Kooby DA, Worhunsky DJ, Jin LX, Hawkins WG, Acher AW, Cho CS, Saunders N, Levine EA, Schmidt CR, Maithel SK, Pawlik TM.

Surgery. 2017 Aug;162(2):285-294. doi: 10.1016/j.surg.2017.03.023. Epub 2017 May 31.

36.

Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?

Tran TB, Norton JA, Ethun CG, Pawlik TM, Buettner S, Schmidt C, Beal EW, Hawkins WG, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Idrees K, Isom CA, Hatzaras I, Shenoy R, Maithel SK, Poultsides GA.

J Gastrointest Surg. 2017 Aug;21(8):1245-1253. doi: 10.1007/s11605-017-3440-z. Epub 2017 May 11.

37.

Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.

Ohman KA, Liu J, Linehan DC, Tan MC, Tan BR, Fields RC, Strasberg SM, Hawkins WG.

HPB (Oxford). 2017 May;19(5):449-457. doi: 10.1016/j.hpb.2017.01.012. Epub 2017 Feb 3.

38.

The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.

Hashim YM, Vangveravong S, Sankpal NV, Binder PS, Liu J, Goedegebuure SP, Mach RH, Spitzer D, Hawkins WG.

J Exp Clin Cancer Res. 2017 Jan 17;36(1):14. doi: 10.1186/s13046-016-0470-4.

39.

Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator.

Cusworth BM, Krasnick BA, Nywening TM, Woolsey CA, Fields RC, Doyle MM, Liu J, Hawkins WG.

HPB (Oxford). 2017 Feb;19(2):147-153. doi: 10.1016/j.hpb.2016.10.015. Epub 2016 Dec 8.

40.

Pattern of Venous Collateral Development after Splenic Vein Occlusion in an Extended Whipple Procedure (Whipple at the Splenic Artery) and Long-Term Results.

Rosado ID, Bhalla S, Sanchez LA, Fields RC, Hawkins WG, Strasberg SM.

J Gastrointest Surg. 2017 Mar;21(3):516-526. doi: 10.1007/s11605-016-3325-6. Epub 2016 Dec 5.

PMID:
27921207
41.

Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study.

Brauer DG, Strand MS, Sanford DE, Kushnir VM, Lim KH, Mullady DK, Tan BR Jr, Wang-Gillam A, Morton AE, Ruzinova MB, Parikh PJ, Narra VR, Fowler KJ, Doyle MB, Chapman WC, Strasberg SS, Hawkins WG, Fields RC.

HPB (Oxford). 2017 Feb;19(2):133-139. doi: 10.1016/j.hpb.2016.11.002. Epub 2016 Dec 1.

42.

Operative Site Drainage after Hepatectomy: A Propensity Score Matched Analysis Using the American College of Surgeons NSQIP Targeted Hepatectomy Database.

Brauer DG, Nywening TM, Jaques DP, Doyle MB, Chapman WC, Fields RC, Hawkins WG.

J Am Coll Surg. 2016 Dec;223(6):774-783.e2. doi: 10.1016/j.jamcollsurg.2016.09.004. Epub 2016 Oct 26.

43.

Timing of Surgical Repair After Bile Duct Injury Impacts Postoperative Complications but Not Anastomotic Patency.

Dominguez-Rosado I, Sanford DE, Liu J, Hawkins WG, Mercado MA.

Ann Surg. 2016 Sep;264(3):544-53. doi: 10.1097/SLA.0000000000001868.

PMID:
27433902
44.

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo DG.

Nat Med. 2016 Aug;22(8):851-60. doi: 10.1038/nm.4123. Epub 2016 Jul 4.

45.

Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.

Ohman KA, Hashim YM, Vangveravong S, Nywening TM, Cullinan DR, Goedegebuure SP, Liu J, Van Tine BA, Tiriac H, Tuveson DA, DeNardo DG, Spitzer D, Mach RH, Hawkins WG.

Oncotarget. 2016 Jun 7;7(23):33529-41. doi: 10.18632/oncotarget.9551.

46.

Single institution results of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of pancreas in 78 patients.

Grossman JG, Fields RC, Hawkins WG, Strasberg SM.

J Hepatobiliary Pancreat Sci. 2016 Jul;23(7):432-41. doi: 10.1002/jhbp.362. Epub 2016 Jun 23.

PMID:
27207482
47.

Perception Is Reality: quality metrics in pancreas surgery - a Central Pancreas Consortium (CPC) analysis of 1399 patients.

Abbott DE, Martin G, Kooby DA, Merchant NB, Squires MH, Maithel SK, Weber SM, Winslow ER, Cho CS, Bentrem DJ, Kim HJ, Scoggins CR, Martin RC, Parikh AA, Hawkins WG, Ahmad SA.

HPB (Oxford). 2016 May;18(5):462-9. doi: 10.1016/j.hpb.2015.11.006. Epub 2016 Mar 2.

48.

Erratum: Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology.

Tatzel K, Kuroki L, Dmitriev I, Kashentseva E, Curiel DT, Goedegebuure SP, Powell MA, Mutch DG, Hawkins WG, Spitzer D.

Sci Rep. 2016 May 4;6:25217. doi: 10.1038/srep25217. No abstract available.

49.

Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane.

Su Y, Tatzel K, Wang X, Belt B, Binder P, Kuroki L, Powell MA, Mutch DG, Hawkins WG, Spitzer D.

Oncotarget. 2016 May 24;7(21):31534-49. doi: 10.18632/oncotarget.8925.

50.

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC.

Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4.

Supplemental Content

Loading ...
Support Center